Analysis of the expression of Ephrin As and its diagnostic value in hepatocellular carcinoma based on the cancer genome atlas dataset
WANG Junjun1 FANG Xuefen2 LIN Qiuyan2#br#
1.Department of Clinical Laboratory, Fujian Provincial Jinshan Hospital, Fujian Province, Fuzhou 350028, China;
2.Department of Gastroenterology, Fujian Medical University Union Hospital, Fujian Province, Fuzhou 350001, China
Objective To investigate the new genes associated with the occurrence of hepatocellular carcinoma (HCC)by analyzing the transcriptome database downloaded from the cancer genome atlas (TCGA) database. Methods The mRNA expression profiles and associated clinical data, including 347 liver cancer tissues and 50 normal tissues, were obtained from TCGA database, and R software was used to explore the mRNA expression differences of Ephrin A1-5(EFNA1-5).The biomarker combined of multi EFNAs was established by logistic model.HCC group was divided into four group according to the Stage Ⅰ-Ⅳ, and each group was compared to the normal group.Receiver operating characteristic (ROC) curve was used to access the diagnostic value of one Ephrin As (EFNAs) and such biomarker combined of multi EFNAs in predicating the occurrence and progression of HCC. Results The mRNA expressions of EFNA1, EFNA3 and EFNA4 in HCC group were higher than those in the normal group, while the mRNA expressions of EFNA2 and EFNA5 were lower than those in the normal group, the differences were statistically significant (P＜0.01).The area under the curve (AUC) of the biomarker combined of EFNA3 and EFNA4 was 0.923, its sensitivity was 0.879 and specificity was 0.880.Furthermore, the AUC of the biomarker combined of EFNA3 and EFNA4 was 0.908, 0.946, 0.938 respectively in predication of HCC progression such as Stage Ⅰ, Ⅱ, Ⅲ, which was higher than that of single EFNAs(P＜0.01). Conclusion EFNAs maybe a valuable biomarker in predicating the occurrence of HCC, especially the synergistical predication biomarker combined of EFNA3 and EFNA4.
王军军； 方雪芬； 林秋燕. 基于癌症基因图谱数据库分析Ephrin As在肝癌中的表达及评估肝癌发生的价值[J]. 中国当代医药, 2022, 29(23): 78-83.
WANG Junjun1 FANG Xuefen2 LIN Qiuyan2. Analysis of the expression of Ephrin As and its diagnostic value in hepatocellular carcinoma based on the cancer genome atlas dataset. 中国当代医药, 2022, 29(23): 78-83.
Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71（3）：209-249.
Hilmi M，Vienot A，Rousseau B，et al.Immune Therapy for Liver Cancers[J].Cancers（Basel），2019，12（1）：77.
[4]
Kania A，Klein R.Mechanisms of ephrin-Eph signalling in development，physiology and disease[J].Nat Rev Mol Cell Biol，2016，17（4）：240-256.
[5]
Ieguchi K，Maru Y.Roles of EphA1/A2 and ephrin-A1 in cancer[J].Cancer Sci，2019，110（3）： 841-848.
[6]
Gao Z，Han X，Zhu Y，et al.Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling[J].Cell Death Dis，2021，12（5）：414.
[7]
Liang Z，Wang X，Dong K，et al.Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis：Revealing Its Importance in Chemotherapy[J].Biomed Res Int，2021，2021：5575704.
[8]
Zhang H，Li Y，Wang HB，et al.Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry[J].Nat Microbiol，2018，3（2）：1-8.
[9]
Ishigaki H，Minami T，Morimura O，et al.EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest[J].Biochem Biophys Res Commun，2019，519（4）：846-853.
[10]
Kaczmarek R，Zimmer K，Gajdzis P，et al.The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases[J].Int J Mol Sci，2021，22（9）： 4567.
[11]
Toma MI，Erdmann K，Diezel M，et al.Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma[J].PLoS ONE，2014，9（7）：e102262.
[12]
Baudet S，Bécret J，Nicol X.Approaches to Manipulate Ephrin-A：EphA Forward Signaling Pathway[J].Pharmaceuticals（Basel），2020，13（7）：140.
[13]
Iida H，Honda M，Kawai HF，et al.Ephrin-A1 expression contributes to the malignant characteristics of fetoprotein producing hepatocellular carcinoma[J].Gut，2005，54（6）：843-851.
[14]
Wada H，Yamamoto H，Kim C，et al.Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma[J].Int J Oncol，2014，45（3）：1051-1058.
Gómez-Maldonado L，Tiana M，Roche O，et al.EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination[J].Oncogene，2015，34（20）：2609-2620.
[17]
DamelinM，BankovichA，ParkA，etal.Anti-EFNA4Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions[J].Clin Cancer Res，2015，21（18）：4165-4173.
[18]
Wang TH，Yeh CT，Ho JY，et al.OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma[J].Mol Carcinog，2016，55（4）：366-375.
[19]
Wang TH, Ng KF, Yeh TS，et al.Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma[J].PLoS One，2012，7（7）：e41749.
[20]
Light TP，Gomez-Soler M，Wang Z，et al.A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain[J].J Biol Chem，2021，297（1）：100876.
[21]
Deng M，Tong R，Zhang Z，et al.EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma[J].Cancer Cell Int，2021，21（1）：535.
京公网安备 11010502046607号